News

BASF Adopts BrightSpec’s Broadband MRR Technology for Structural Elucidation

BrightSpec announced the start of operation of a broadband Molecular Rotational Resonance spectrometer at BASF’s research center in Ludwigshafen, Germany.

BASF will utilize MRR spectroscopy for the concise structure elucidation of organic compounds where isomerism is an underlying question. Major applications comprise stereochemical analysis, including chirality, defining the composition of mixtures without purification, and the facile structural analysis of gas-phase samples. Implementing MRR as a technology was driven by Senior Principal Scientists Wolf Stegmaier and Reinhard Doetzer of BASF’s Competence Center Analytics.

“MRR is an excellent tool for elucidating structures in combination with the classical methods FTIR, MS, and NMR since it provides critical information orthogonal to them,” stated Dr. Doetzer.  He continued: “We leverage MRR to increase the accuracy and speed of the structure elucidation process, boosting our analytical productivity.  Not a day goes by when I don’t think of a sample for which MRR would be the perfect method for solving a structure-related problem.”

Dr. Wolf Stegmaier added: “In gas analysis, MRR is providing quick answers for polar analytes without gas chromatographic separation or special detection systems. Its high selectivity is a great help in the direct analysis of complex gas samples; this is particularly so for the quantification of analytes in mixtures.”

BrightSpec’s Broadband MRR provides the unique ability to identify unknown molecules directly from a crude mixture.  In conjunction with modern quantum-mechanical calculations, MRR allows identifying the unequivocal three-dimensional structure of a molecule without reference standard or front-end separation. This combination increases sample throughput and drastically reduces the cost for many  applications across the Pharmaceutical and Chemical industries.

Director of Business Development at BrightSpec, Dr. Christopher Thompson, commented: “We are thrilled that BASF has adopted our MRR platform into their analytical workflows.  The installation is a testament to the capabilities of the entire BrightSpec team.  The close partnership between scientists at BrightSpec and BASF will ensure the success of the Broadband MRR over the coming years.”

Walter Colsman, BrightSpec’s CEO, stated, “I am extremely proud to officially announce our relationship with BASF. Both companies see the broad potential for MRR at BASF, extending beyond the lab and into operations, and we will work together to develop BASF’s MRR platform.  For example, BASF’s broadband MRR will help develop routine applications that are suitable to run on BrightSpec’s isoMRR, enabling rapid, targeted applications such as online process analytics or quality control.”

Recent News

10/23/2026

PAK BioSolutions and iBET Advance Integrated Continuous AAV8 Purification

PAK BioSolutions today announced the publication of a peer-reviewed study on integrated, continuous purification of adeno-associated virus serotype 8 (AAV8) using the PAK PD™ Process Development Scale Continuous Purification System. Conducted in collaboration with iBET – Instituto de Biologia Experimental e Tecnológica, the study, “Streamlining AAV8 Purification with Cyclic Integrated Capture–Polishing Chromatography,” was published in …

10/22/2026

Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020

Eli Lilly and Company (NYSE: LLY) broke ground today on a new $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County, one of 10 new U.S. manufacturing sites announced since 2020 and one of five among them that will produce active pharmaceutical ingredients (API). As part of the company’s more than $50 …

10/21/2026

United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the opening of its third Designated Pathogen-Free (DPF) facility, The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility, in Houston, Texas. United Therapeutics opened its first DPF facility in Christiansburg, Va. in 2024 to produce xenografts for ongoing clinical trials. …